Text Messaging and Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01216059
Recruitment Status : Completed
First Posted : October 7, 2010
Last Update Posted : December 3, 2012
Information provided by (Responsible Party):
Amy Paller, Northwestern University

Brief Summary:
Atopic dermatitis is a common problem faced by patients of all ages and backgrounds. Treatment regimens and specific therapies may be time consuming and multiple studies have documented a parallel decrease in compliance as time after an office visit increases. The adolescent population is an extremely challenging sub-group of patients in terms of complying with a treatment regimen. Not only are they striving for independence and thus lacking supervision of a regimen by a parent, but their complex thinking skills are immature, leading to forgetful behavior. By introducing a reminder system for these vulnerable patients that is easily incorporated into their daily lives, the investigators propose that patients will have better compliance at applying their medication and thus improving their atopic dermatitis. Text-messaging via cell phones has become very popular among teenagers and adults and provides a non-obtrusive method of sending a treatment reminder.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Procedure: Text message to cell phone Not Applicable

Detailed Description:
We propose to conduct a randomized, controlled 6-week trial to evaluate the impact of a text message-based reminder program on adherence to health maintenance behaviors among adolescents diagnosed with Atopic Dermatitis. After obtaining informed consent, subjects will be randomized into either an intervention or control group. Subjects in the intervention group will receive a daily text message with a tailored message regarding atopic dermatitis, while control group subjects will receive a weekly text message with information on local weather, sport or news without any reference to atopic dermatitis. Of note, the decision to send a weekly text message to the control group reflects the expectation that a message will be sent, although the frequency and content of the message will not be revealed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis
Study Start Date : October 2010
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Intervention group
Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
Procedure: Text message to cell phone
Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
No Intervention: Control Group
Subjects will receive a weekly text message reminder about pop-culture, sports or weather.

Primary Outcome Measures :
  1. Change in self reported medication adherence [ Time Frame: 6 weeks ]
    We will assess the difference in number of missed doses of topical medication in the control group (weekly unrelated text message) and the intervention group (daily eczema-related text message group). All subjects will record missed doses via calendars (diaries). Those in the intervention group will be able to text on a weekly basis the number of days they forgot their medication that week.

  2. Change in quality of life [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Change in AD knowledge score [ Time Frame: 6 weeks ]
  2. Change in health maintenance behaviors [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 10-17 inclusive
  • Capable of giving informed consent/assent. Of note, all subjects will sign an assent form and parents will sign a parent consent form.
  • Diagnosed with Atopic Dermatitis by a physician (self report)
  • IGA score fo 2 or greater
  • Currently using at least one prescribed topical therapy for atopic dermatitis
  • Have a mobile phone capable of receiving text messages
  • Able to retrieve text messages from mobile phone
  • Able to adhere to study visit schedule and other protocol requirements.

Exclusion Criteria:

  • Younger than 10 years of age or 18 years and older at the time of enrollment
  • No diagnosis of atopic dermatitis by a physician
  • IGA score of 0 or 1
  • Currently on no prescribed topical treatment for atopic dermatitis
  • UV therapy or climatotherapy is a part of treatment for atopic dermatitis
  • Does not have a mobile phone capable of receiving text messages
  • Unable to retrieve text message
  • Non-English speaking individuals (text messages are in English)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01216059

United States, Illinois
Northwestern University Feinberg School of Medicine, Department of Dermatology
Chicago, Illinois, United States, 60611
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
Sponsors and Collaborators
Northwestern University
Principal Investigator: Amy Paller, MD Northwestern University

Responsible Party: Amy Paller, Professor and Chair of Department of Dermatology, Professor of Pediatrics, Northwestern University Identifier: NCT01216059     History of Changes
Other Study ID Numbers: STU29486
First Posted: October 7, 2010    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: November 2012

Keywords provided by Amy Paller, Northwestern University:
text message

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases